SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trading significantly lower following reports that merger discussions with Merck have collapsed due to disagreements over valuation. Despite the immediate sell-off, community sentiment remains split between investors bracing for further downside and those viewing the dip as a long-term entry point given the company's strong clinical data in RAS-targeted oncology.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies is trending as the market prices in the potential for a gamma squeeze, fueled by its low float and persistent institutional buying pressure. Community discussion remains heavily focused on the stock's role as an asymmetric proxy for the HYPE token and broader decentralized finance infrastructure.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is currently trending due to its surge in institutional interest and significant trading volume, as it establishes itself as a leader in decentralized perpetual futures. The community is actively discussing its record-breaking fee buybacks, the anticipation of new crypto-related regulatory developments, and its role as a high-performance alternative to traditional assets.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors digest the company's recent ASCO plenary presentation, which showcased compelling overall survival data for its ivonescimab lung cancer treatment. The community is heavily focused on the clinical implications of beating the current standard of care and the company's path toward regulatory milestones, despite ongoing debates regarding clinical trial design and short-term volatility.

Gitlawb is a decentralized code collaboration platform designed for AI agents and human developers. It provides a Git-compatible hosting layer where repositories are stored across IPFS, Filecoin, and Arweave, and peer connectivity is handled through libp2p rather than a central server.  Identity on Gitlawb is based on decentralized identifiers (DIDs) using Ed25519 keys. Access control and delegation between users and agents are expressed as UCAN (User Controlled Authorization Networks) capabilities, allowing scoped, revocable permissions to be granted without a central authority. Each identity carries an on-chain trust score derived from verified contributions.  The protocol is accessed through three main surfaces: a Rust node (gitlawb-node) that serves repositories over HTTP and libp2p, a command-line client (gl) that handles identity, repositories, issues, bounties, and UCAN delegation, and a git remote helper (git-remote-gitlawb) that allows standard Git clients to push and pull using gitlawb:// URLs.  Additional products in the ecosystem include MiroClaw, an on-chain prediction market; Gitlawb Spawn, an AI agent orchestration tool; OpenClaude, an open-source agent harness aligned with Playground and Spawn; and a developer playground for testing agent interactions against the protocol.

Gitlawb

Gitlawb is garnering significant attention as a decentralized, AI-native infrastructure project positioned to compete with centralized coding platforms by enabling autonomous agents to manage repositories on-chain. Investors are actively discussing the project's utility-driven tokenomics, aggressive supply reduction strategies, and strategic partnerships, fueling speculation about potential exchange listings and future growth.

Zoracles

Zoracles is seeing active community discussion as investors debate its long-term potential against a backdrop of broader crypto market volatility and recent downward pressure. Many users are focusing on accumulation and the importance of patience, highlighting upcoming regulatory catalysts and platform utility as primary drivers for a potential recovery.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche (AVAX) is facing significant downward pressure and intense community frustration as it trades near multi-year lows despite institutional milestones like new ETF launches and RWA tokenization partnerships. Investors are actively debating whether these depressed price levels represent a generational buying opportunity or a signal of long-term structural weakness in the altcoin sector.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is capturing attention as investors debate the impact of the Polkadot 2.0 upgrade and a new supply cap on its long-term value. While some community members remain skeptical, others are closely tracking potential catalysts like ETF developments and increased staking activity to see if the asset can regain momentum.

Gartner, Inc. is a research and advisory company, which engages in the provision of insights, advice, and tools that help build organizations. It operates through the following segments: Insights, Consulting, Conferences, and Other. The Insights segment equips executives and their teams from every major function, geography, industry and sector with actionable, objective insights, guidance, and tools. The Consulting segment serves the chief information officer and other senior executives who are driving technology-driven strategic initiatives to optimize technology investments and drive business impact. The Conferences segment focuses on information technology and business executives as well as decision makers looking to adapt and evolve their organizations through disruption and uncertainty, navigate risks, and prioritize investments. The company was founded by Gideon I. Gartner and Dave L. R. Stein in 1979 and is headquartered in Stamford, CT.

Gartner, Inc.

Gartner is trending as investors weigh its potential as a long-term enterprise technology bellwether against concerns over slowing contract value growth and potential legal scrutiny regarding its consulting outlook. The community remains divided, with bulls highlighting its essential role in AI adoption cycles, while bears focus on recent price weakness and the competitive threat posed by generative AI to traditional advisory models.

Las Vegas Sands Corp. engages in the development of destination properties. It operates through the Macao and Singapore geographical segments. The Macao segment handles the operations of The Venetian Macao, The Londoner Macao, The Parisian Macao, The Plaza Macao and Four Seasons Macao, and Sands Macao. The Singapore segment includes the Marina Bay Sands. The company was founded by Sheldon Gary Adelson in August 2004 and is headquartered in Las Vegas, NV.

Las Vegas Sands Corp

Las Vegas Sands is seeing increased attention as the community weighs potential bull flag breakout setups against concerns over the company's reliance on the Macau market and internal leadership dynamics. Investors are actively debating the stock's long-term valuation, with many monitoring the balance between regional growth opportunities and the impact of the company's dividend and buyback programs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on...

Joanne Donovan Sells 50,000 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 50,000 shares of the firm's stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the transaction, the...

Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells $163,646.70 in Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 5,230 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $31.29, for a total value of $163,646.70. Following the sale, the chief marketing officer owned...

CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?

Equity

The company said Aficamten for patients with symptomatic non-obstructive hypertrophic cardiomyopathy met both primary endpoints.

Edgewise Therapeutics (NASDAQ:EWTX) Sets New 52-Week High  - Should You Buy?

Edgewise Therapeutics (NASDAQ:EWTX) Hits New 1-Year High - Time to Buy...

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Analysts

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, MarketBeat.com...

Edgewise Therapeutics (EWTX) to Release Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Moody Aldrich Partners LLC Has $1.07 Million Holdings in Edgewise Therapeutics, Inc. $EWTX

Moody Aldrich Partners LLC cut its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 48.0% in the fourth quarter, according to the company in its most recent filing with the...

Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Here's What Happened

Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Should You Buy...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Current Price	$34.16
Prev Close	$33.30
Open	$33.18
Dividend Yield	0.00%
50-Day Moving Average	$32.66
Beta	1.42
Avg. Volume	990,254.29
PE Ratio	-20.57

52-Week High	$39.96
52-Week Low	$12.15
Market Capitalization	$3.68B
EPS (Annual)	-$1.63
Price to Book	7.44
Revenue Per Employee	$0.00

EWTX
Edgewise Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest EWTX News

EWTXEdgewise Therapeutics Inc